GLP-1 Receptor Agonists Improve HS in Patients With Obesity
Investigators reported that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were associated with significant improvements in clinical severity, patient-reported outcomes, and weight in patients with hidradenitis suppurativa (HS) and obesity.
METHODOLOGY:
The retrospective multicenter cohort study evaluated 66 adults (median age, 46 years; 58% women) with HS who received semaglutide, dulaglutide, or liraglutide for at least 3 months, using data from eight French hospitals, between 2017 and 2024.
Their median BMI was 39.4, and 86% of patients had diabetes; 45%, 32%, and 23% of patients had Hurley stages I, II, and III disease, respectively.
Outcomes included HS-Physician's Global Assessment (HS-PGA), flare frequency, Numerical Rating Scale (NRS)-Pain, NRS-Suppuration, Dermatology Life Quality Index (DLQI), and BMI at 6 months.
Median follow-up was 18.5 months.
TAKEAWAY:
At 6 months, 54% of patients had achieved at least one-point reduction in HS-PGA and 12% of patients demonstrated at least two-point reduction; flares were reduced in 60% patients.
NRS-Pain scores decreased in 52% of patients, NRS-Suppuration scores decreased in 53% patients, and improved quality of life, based on DLQI scores, was observed in 50% patients at 6 months.
Among 34 patients with stable HS treatment, all outcome measures showed statistically significant improvements at 6 months (P < .001).
Median BMI decreased from 39.4 to 37.2 at 6 months.
IN PRACTICE:
'GLP-1 RAs offer promise for patients with HS and obesity and potentially for patients without obesity through immunological effects,' the study authors wrote. 'Randomized clinical trials are warranted to confirm the role of GLP-1 RAs in HS management,' they added.
SOURCE:
The study was led by Louise Gouvrion, MD, Department of Dermatology, Rennes University Hospital in Rennes, France, and was published online on August 13 in JAMA Dermatology.
LIMITATIONS:
The retrospective design, concurrent use of diverse HS therapies, potential selection bias, and absence of glycemic and inflammatory biomarker data limit causal inference.
DISCLOSURES:
The authors did not disclose any funding information. Several authors reported receiving personal fees, conference invitations, nonfinancial support from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Lilly, Janssen, LEO Pharma, MSD, Novartis, UCB, and others.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
5 minutes ago
- Medscape
Pluvicto vs ARPI in Prostate Cancer: Is One Better?
TOPLINE: Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who switched androgen receptor pathway inhibitors (ARPI) after progressing on a first-line ARPI. However, the authors noted, the overall survival results "were likely confounded by the high rate of crossover" from a second-line ARPI to Lu-177-PSMA-617. METHODOLOGY: Patients with metastatic castration-resistant prostate cancer who progress on first-line ARPI therapy and are taxane-naive may receive an ARPI in the second-line setting if they are unable to tolerate taxane-based chemotherapy. However, an ARPI is not the most active treatment in this setting. In the PSMAfore trial , researchers compared the efficacy of another agent — Lu-177-PSMA-617 — to an ARPI as a second-line treatment option. Overall, 468 patients with PSMA-positive metastatic castration-resistant prostate cancer were randomly assigned to receive either Lu-177-PSMA-617 (n = 234) or ARPI switch (n = 234). Participants had previously experienced disease progression on an ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide) and were deemed appropriate to delay taxane-based chemotherapy. Participants received Lu-177-PSMA-617 at a dose of 7.4 GBq once every 6 weeks for six cycles or ARPI change (abiraterone or enzalutamide at the treating physician's discretion). Patients in the ARPI arm could cross over to Lu-177-PSMA-617 after centrally confirmed radiographic progression. In the initial analysis, radiographic progression-free survival appeared longer in patients receiving Lu-177-PSMA-617 compared to a second-line ARPI. During the final analysis , 60.3% of participants (141 of 234) randomly assigned to the ARPI switch group crossed over to receive Lu-177-PSMA-617, representing 75.4% of patients with confirmed radiographic progression. The median duration of exposure was 8.41 months in the Lu-177-PSMA-617 arm, 6.54 months in the ARPI-change arm, and 7.16 months in the crossover group. TAKEAWAY: Median overall survival was similar in both groups: 24.48 months with Lu-177-PSMA-617 vs 23.13 months with ARPI change (hazard ratio [HR], 0.91; P = .20), according to the intention-to-treat analysis. In a crossover-adjusted analysis, patients receiving Lu-177-PSMA-617 demonstrated a significant survival benefit (HR, 0.59), which "suggested that treatment crossover likely confounded [overall survival]," the authors wrote. Treatment-emergent adverse events of grade 3 or higher were lower in the Lu-177-PSMA-617 group, as were rates of serious adverse events of any grade. In the Lu-177-PSMA-617 arm, more common adverse events included dry mouth and anemia. Dry mouth of any grade occurred in nearly 60% of participants, with less than 1% experiencing events of grade 3 or higher. Anemia of any grade occurred in about 27% of patients, with 6.2% experiencing events of grade 3 or higher. These events were predominantly low grade and resolved or were resolving at the final analysis. IN PRACTICE: Taken together with the previous observations from PSMAfore, "these results further support 177Lu-PSMA-617 as an alternative treatment option to ARPI change" in this patient population, the authors wrote. SOURCE: The study, led by Karim Fizazi, PhD, Institut Gustave Roussy and Centre Oscar Lambret, Université Paris-Saclay in Villejuif, France, was published online in Annals of Oncology. LIMITATIONS: The high rate of crossover probably confounded the overall survival analysis. The study excluded patients with known genomic alterations, limiting generalizability. Additionally, the trial may have been underpowered to detect an overall survival difference between arms, a limitation further exacerbated by the high crossover rate. DISCLOSURES: This study was funded by Novartis. Four authors reported being employees of and receiving restricted stock options from Novartis. Several authors reported receiving research grants or honoraria and having other ties with various sources. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
34 minutes ago
- Yahoo
BCC Research Forecasts 11.8% CAGR for Superconductors Market Through 2030
"Market report explores the growing use of superconductors across the healthcare, energy, and transportation industries, with insights into the different types, materials, and regional trends driving future growth." BOSTON, Aug. 14, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Superconductors: Global Markets" is expected to grow from $9.4 billion in 2025 to $16.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2025 to 2030. This report offers a comprehensive analysis of the global superconductor market. It breaks down the market by type, material, application, and region, covering the geographical segments of North America, Europe, Asia-Pacific, and the Rest of the World. The study highlights emerging technologies, examines the competitive vendor landscape, and concludes with detailed profiles of major industry players. This report is particularly relevant today due to the growing global interest and investment in advanced technologies like nuclear fusion and magnetic levitation (maglev) trains, which rely on superconductors. It provides stakeholders with a detailed analysis of market segments, trends, growth opportunities, and challenges, helping industrial companies and investors make informed decisions. As innovation accelerates, understanding the dynamics of the superconductor market is crucial for staying competitive and driving technological advances. The factors driving the market's growth include: Fusion Energy Projects: Fusion energy projects like ITER require superconductors for powerful magnetic fields to contain plasma. Their ability to carry high currents without resistance makes them essential for advancing clean energy technologies. Use of Superconductors in Cables and Maglev Trains: Superconducting cables reduce energy loss in power transmission, while maglev trains use superconducting magnets for frictionless, high-speed travel. These applications are expanding in countries focused on modern infrastructure. Global Drive To Sustainability: Superconductors support sustainability by improving energy efficiency in grids, transportation, and renewable systems. Their role in reducing carbon emissions aligns with global environmental goals. Advent of Green Superconductors: Green superconductors are made from non-toxic, abundant materials and require less cooling, making them eco-friendlier and more suitable for sustainable industrial use. Novel Superconductor Materials: New materials like iron-based and hydride superconductors offer better performance and higher operating temperatures, broadening their commercial and industrial applications. Room-Temperature Superconductors: Breakthroughs in room-temperature superconductors eliminate the need for costly cooling, making superconducting technologies more practical and scalable across industries. Request a sample copy of the global market for superconductors report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $9 billion Market size forecast $16.4 billion Growth rate CAGR of 11.8% for the forecast period of 2025-2030 Segments covered Type, Material, Application, and Region Regions covered North America, Europe, Asia-Pacific, Rest of the World Countries covered U.S., Canada, Mexico, U.K., Germany, France, China, Japan, South Korea, South America, and the Middle East and Africa Market drivers • Rising fusion energy projects globally. • Increasing adoption of superconductors in cables and maglev trains. • Growing global drive toward sustainability. • Advent of green superconductors. • Evolution of novel superconductor materials. • Emergence of room-temperature superconductors Interesting facts: The niobium-based material type dominated the global superconductor market with an 80.0% share, and this segment is expected to reach $12,985.5 million by the end of 2030, driven by higher use in MRI applications and higher availability. North America has the largest share of the market. This dominance is due to the higher demand for MRI machines, technological advances in superconductors, and government-backed nuclear fusion-related projects across the region. Future trends like rising investments in nuclear fusion, power transmission, and maglev trains are unlocking new superconductor market opportunities. Still, sustained growth depends on the successful commercialization of these high-potential applications. Emerging startups: Unearthly Materials is a company that develops ambient-temperature superconductor materials. High-temperature superconductors produce superconducting wires. Orion Industries builds room-temperature superconductors using diamond materials. The report addresses the following questions: What are the global superconductor market's projected size and growth rate?The global superconductor market was valued at $9 billion in 2024 and is projected to reach $16.4 billion by the end of 2030, growing at a CAGR of 11.8% from 2025 to 2030. Which factors are driving the growth of the global superconductors market?Rising global investments in fusion energy projects, rapid adoption of superconductors in maglev trains and power transmission systems, and the global push toward sustainability and carbon-neutral technologies fuel demand for superconductors worldwide. What are the challenges and opportunities in the market?The rise of global fusion energy projects and superconducting applications in maglev trains, power grids, and sustainable technologies is creating strong momentum for adoption and investment. However, the high costs of raw materials, production, and cryogenic maintenance make superconductors economically unviable for large-scale deployment. Which superconductor type will be dominant through 2030?The LTS segment is expected to continue dominating the global superconductor market through the end of 2030, driven by its widespread adoption in MRI applications. Which region has the highest share in the global market?In 2024, North America accounted for $4.4 billion in revenue, representing about 48.3% of the global superconductor market. Market leaders include: AMERICAN SUPERCONDUCTOR BRUKER FARADAY FACTORY JAPAN FUJIKURA LTD. FURUKAWA ELECTRIC CO. LTD. HYPRES INC. LS CABLE & SYSTEM LTD. LUVATA METOX INTERNATIONAL NEXANS SHANGHAI SUPERCONDUCTOR TECHNOLOGY CO. LTD. SUMITOMO ELECTRIC INDUSTRIES LTD. SUNAM CO. LTD. SUPERPOWER INC. THEVA DUNNSCHICHTTECHNIK GMBH Related reports include: Quantum Computing: Technologies and Global Markets to 2030: This report provides a detailed review of the global quantum computing market, analyzing trends, challenges, and opportunities across segments such as offerings, deployment modes, technologies, applications, and end-user industries. It covers North America, Europe, Asia-Pacific, and the Rest of the World, and explores the regulatory environment, ESG developments, patent activity, and emerging technologies. Additionally, it analyzes the competitive landscape with profiles of leading companies and their market strategies. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
DexCom Stock: Analyst Estimates & Ratings
DexCom, Inc. (DXCM), headquartered in San Diego, California, is a global leader in the development and manufacturing of continuous glucose monitoring (CGM) systems. The company primarily serves people with diabetes by offering advanced, real-time monitoring solutions that track glucose levels, enabling more precise and proactive diabetes management. DexCom's flagship products include the DexCom G6 and G7 systems, which provide users with continuous, non-invasive data for better glucose control. Beyond diabetes, DexCom is expanding into areas like diabetes prevention and insulin dosing optimization, positioning itself as a key player in the evolving healthcare and medical device sectors. The company has a market capitalization of $31.36 billion. More News from Barchart Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Shares of this medical device company have gained 12.6% over the past 52 weeks, underperforming the broader S&P 500 Index ($SPX), which has gained 19% over the same period. This year, the stock has gained a modest 2.8%, while the S&P 500 index is up almost 10% year-to-date (YTD). To put this into perspective, we compare with the sector-specific iShares U.S. Medical Devices ETF (IHI). The ETF's gains have more or less aligned with DexCom's, rising by 10.3% over the past 52 weeks and 5.9% on a YTD basis. Despite DexCom's strong second-quarter results on Jul. 30, the market's reaction was not positive, as the stock price dropped a notable 9.3% the very next trading session. The company's revenue increased 15.2% year-over-year (YOY) to $1.16 billion. DexCom also received FDA clearance for the DexCom G7 15 Day CGM System. Its adjusted EPS increased 11.6% YOY to $0.48, surpassing the $0.45 figure expected by Wall Street analysts. For the fiscal year 2025, ending this December, Wall Street analysts expect DexCom's bottom line to grow by 25% YOY to $2.05 per share on a diluted basis. The company has a mixed history of surpassing consensus estimates, topping them in two of the trailing four quarters and missing them on two other occasions. Among the 25 analysts covering DexCom's stock, the consensus is a 'Strong Buy.' That's based on 20 'Strong Buy' ratings, one 'Moderate Buy' rating, and four 'Holds.' The current configuration of the ratings is slightly more bullish than two months ago, when the stock had 19 'Strong Buy' ratings. Reflecting a stable market outlook for the company, Canaccord Genuity analyst William Plovanic maintained a 'Buy' rating on the stock this month, while keeping the price target at $106. On July 31, Raymond James analyst Jayson Bedford maintained a "Strong Buy" rating, with the price target on the stock raised from $99 to $102. DexCom's mean price target of $102.60 indicates a premium of 28.3% from the current market prices. The Street-high price target of $125 implies a potential upside of 56.3%. On the date of publication, Anushka Mukherjee did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
